Effects of intracerebral neurotrophic factor application on motor symptoms in Parkinson's disease: a systematic review and meta-analysis

Show simple item record

dc.contributor.author Hegarty, Shane V.
dc.contributor.author Lee, David J.
dc.contributor.author O'Keeffe, Gerard W.
dc.contributor.author Sullivan, Aideen M.
dc.date.accessioned 2017-02-13T14:21:08Z
dc.date.available 2017-02-13T14:21:08Z
dc.date.issued 2017-02-10
dc.identifier.citation Hegarty, S. V., Lee, D. J., O'Keeffe, G. W. and Sullivan, A. M. (2017) 'Effects of intracerebral neurotrophic factor application on motor symptoms in Parkinson's disease: A systematic review and meta-analysis', Parkinsonism & Related Disorders, 38, pp.19-25 doi:10.1016/j.parkreldis.2017.02.011 en
dc.identifier.volume 38
dc.identifier.startpage 19
dc.identifier.endpage 25
dc.identifier.issn 1353-8020
dc.identifier.uri http://hdl.handle.net/10468/3620
dc.identifier.doi 10.1016/j.parkreldis.2017.02.011
dc.description.abstract Introduction: Neurotrophic factors (NTFs) have been evaluated for neuroprotective effects in Parkinson's disease (PD). However, clinical trials examining the efficacy of intracerebral administration of NTFs on motor symptoms in PD have produced mixed results, and are thus inconclusive. The objective of this systematic review and meta-analysis was to determine the effects of intracerebral NTF application on motor symptoms in people with PD. Methods: We searched PubMed, MEDLINE, EMBASE, and Cochrane from inception through to March 31 2016 for open-label trials and randomized controlled trials (RCTs) which intracerebrally administered NTFs to PD patients, and which performed motor examination of Unified Parkinson's Disease Rating Scale. Results: Eight studies with a total of 223 participants were included. Fixed effects analysis revealed that NTF treatment did not significantly reduce motor symptoms in PD patients compared to placebo controls (P = 0.98). Combining open-label and RCT data, both treatment with NTFs (P < 0.001) and treatment with placebo (P < 0.05) significantly improved motor function in PD patients when compared to predicted symptoms in untreated PD controls. Finally, random effects analysis revealed that NTF-treated PD patients were not significantly likely to improve following intracerebral NTF administration (P = 0.25). Conclusion: In conclusion, intracerebral NTF administration does not improve motor symptoms in PD patients, when compared to placebo-treated controls. These findings may guide therapeutic decisions and inform future research on NTFs and their application in PD. en
dc.description.sponsorship Irish Research Council (R15897; SVH/AS/); The National University of Ireland (R16189; SVH/AS/); en
dc.format.mimetype application/pdf en
dc.language.iso en en
dc.publisher Elsevier en
dc.rights © 2017 Elsevier Ltd. All rights reserved. This manuscript version is made available under the CC-BY-NC-ND 4.0 license. en
dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0/ en
dc.subject Parkinson's disease en
dc.subject Neurotrophic therapy en
dc.subject Clinical trials en
dc.subject Systematic review/meta-analysis en
dc.subject Neurotrophic factors en
dc.title Effects of intracerebral neurotrophic factor application on motor symptoms in Parkinson's disease: a systematic review and meta-analysis en
dc.type Article (peer-reviewed) en
dc.internal.authorcontactother Shane Hegarty, Department Of Anatomy & Neuroscience, University College Cork, Cork, Ireland. +353-21-490-3000 Email: shane.hegarty@ucc.ie en
dc.internal.availability Full text available en
dc.check.info Access to this article is restricted until 12 months after publication by the request of the publisher. en
dc.check.date 2018-02-10
dc.date.updated 2017-02-13T12:57:38Z
dc.description.version Accepted Version en
dc.internal.rssid 383418293
dc.contributor.funder Science Foundation Ireland en
dc.contributor.funder Irish Research Council en
dc.contributor.funder National University of Ireland en
dc.description.status Peer reviewed en
dc.identifier.journaltitle Parkinsonism & Related Disorders en
dc.internal.copyrightchecked No !!CORA!! en
dc.internal.licenseacceptance Yes en
dc.internal.IRISemailaddress shane.hegarty@ucc.ie en
dc.relation.project info:eu-repo/grantAgreement/SFI/SFI Career Development Award/15/CDA/3498/IE/Development of GDF5 neurotrophic factor therapy for Parkinson_s disease./


Files in this item

This item appears in the following Collection(s)

Show simple item record

© 2017 Elsevier Ltd. All rights reserved. This manuscript version is made available under the CC-BY-NC-ND 4.0 license. Except where otherwise noted, this item's license is described as © 2017 Elsevier Ltd. All rights reserved. This manuscript version is made available under the CC-BY-NC-ND 4.0 license.
This website uses cookies. By using this website, you consent to the use of cookies in accordance with the UCC Privacy and Cookies Statement. For more information about cookies and how you can disable them, visit our Privacy and Cookies statement